Celgene Corporation
107.930.41 (0.38%)

After hours: 104.56-3.37 (-3.12%) as of 5:57 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close107.52
Bid104.52 x 100
Ask104.60 x 200
52wk Range92.98 - 136.40
Day's Range106.73 - 108.14
Avg Vol (3m)4,365,147
As of 4:00 PM EDT. Market closed.
  • Reuters30 minutes ago

    Celgene drug fails to extend survival in lymphoma study

    Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use, and its shares fell more than 2 percent. Revlimid, a multiple myeloma treatment with annual sales of about $6 billion, was being tested versus a placebo in patients whose diffuse large B-cell lymphoma had responded to initial treatment with Roche's Rituxan and chemotherapy.

  • TheStreet.com55 minutes ago

    Celgene Can't Expand Revlimid Approval into Non-Hodgkin Lymphoma Just Yet

    Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.